Hostname: page-component-7c8c6479df-94d59 Total loading time: 0 Render date: 2024-03-28T17:10:46.744Z Has data issue: false hasContentIssue false

High dose neuroleptics

Published online by Cambridge University Press:  02 January 2018

Sophia Andrews*
Affiliation:
West Suffolk Hospital, Bury St Edmunds IP33 2QZ
Rights & Permissions [Opens in a new window]

Abstract

Type
The Columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 2001. The Royal College of Psychiatrists

Sir: Wilkie et al's (Psychiatric Bulletin, May 2001, 25, 179-183) study of high dose neuroleptics was timely and informative. However, it is surprising to note that they consider haloperidol 10 mg to be equivalent to chlorpromazine 100 mg. It is generally regarded that 2 mg of haloperidol is equivalent to 100 mg of chlorpromazine (Reference King and KingKing, 1995). Moreover, the highest recommended dose of haloperidol in schizophrenia is 30 mg (British Medical Association & Royal Pharmaceutical Society of Great Britain, 2001) and not 200 mg as the authors suggest. It is well known that doses of haloperidol higher than 12 mg do not produce any additional clinical benefits while causing increasing side-effects. The findings of the present study suggest that high dose neuroleptic prescribing is not based on sound pharmacological principles. Despite the high profile of pharmacological treatments in psychiatry, psychopharmacology does not appear to have a similar status in the psychiatric trainee's curriculum. I hope that the newfound Psychopharmacology Special Interest Group of the College will rectify this anomaly.

References

British Medical Association & Royal Pharmaceutical Society of Great Britain (2001) British National Formulary, London & Wallingford: BMJ Books & Pharmaceutical Press.Google Scholar
King, D. J. (1995) Neuroleptics and the treatment of schizophrenia. In Seminars in Psychopharmacology (ed. King, D. J.), pp. 259327. London: Royal College of Psychiatrists.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.